Market Overview

Benchmark Company Reiterates Buy Rating, $87 PT on Analogic Corporation on Ultrasonix Acquisition

Related ALOG
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Analogic Announces Agreement to Distribute Prostate Guidance Solution

In a report published Friday, Benchmark Company reiterated its Buy rating and $87.00 price target on Analogic Corporation (NASDAQ: ALOG).

Benchmark Company noted, “ALOG announced that the company completed the Ultrasonix Medical acquisition. Ultrasonix Medical is a supplier of advanced ultrasound systems for the point-of-care and general imaging markets with over 5,000 systems installed worldwide. We believe that this acquisition brings multiple benefits including an expanded product line, additional customers for cross-selling opportunities and an expanded sales channel including the sales and marketing infrastructure.”

Analogic Corporation closed on Thursday at $74.00.

Posted-In: Benchmark CompanyAnalyst Color Reiteration Analyst Ratings


Most Popular

Related Articles (ALOG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free